platinum has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (23.64) | 24.3611 |
| 2020's | 42 (76.36) | 2.80 |
| Authors | Studies |
|---|---|
| Chua, YJ; Noguchi, E; Shimoi, T; Sudo, K; Yonemori, K | 1 |
| Shimanuki, Y; Shimizu, C; Shimomura, A; Terakado, H; Yoshimura, K | 1 |
| Connell, PP; Li, X; Liang, X; Liu, S; Sun, X; Yang, W; Yuan, X; Zuo, K | 1 |
| Adalsteinsson, VA; Asad, S; Collier, KA; Ha, G; Jenison, J; Lin, NU; Mardis, ER; Parsons, HA; Rajkovic, A; Stover, DG; Tallman, D; Tolaney, SM; Winer, EP | 1 |
| Bruzzone, M; Ceppi, M; Conte, B; de Azambuja, E; Del Mastro, L; Fregatti, P; Lambertini, M; Poggio, F; Punie, K; Tagliamento, M | 1 |
| Jia, Y; Liu, Y; Lu, Y; Nong, L; Qin, F; Tan, A; Tang, J; Wang, H; Xie, W; Zhong, W; Zhou, W | 1 |
| Guan, X; Hu, Y; Tang, C; Zhang, W; Zhu, Y | 1 |
| Gao, SL; Kang, YK; Wang, X; Yuan, P; Yue, J | 1 |
| Bieńkowski, M; Jassem, J; Tomasik, B | 1 |
| Appleman, L; Belani, CP; Beumer, JH; Chen, A; Chew, H; Chu, E; Diergaarde, B; Ding, F; Duan, W; Garcia, AA; Giranda, V; Hurley, RM; Ivy, SP; Ji, J; Katz, T; Kaufmann, SH; Kiesel, BF; Lee, JJ; Lin, Y; Manzo, J; Morgan, RJ; Oesterreich, S; Pahuja, S; Parchment, RE; Puhalla, S; Shepherd, SP; Stoller, R; Swisher, EM; Tan, AR; Tawbi, H; Visscher, DW; Wahner Hendrickson, AE; Yu, J; Zhang, Y | 1 |
| Abrahamse, P; Caswell-Jin, JL; Gomez, SL; Hamilton, AS; Hofer, TJ; Katz, SJ; Kurian, AW; Ward, KC | 1 |
| Banda, K; Chandok, H; Dobrolecki, L; Kumar, P; Lewis, MT; Liu, ET; Menghi, F; Radke, MR; Rodriguez, IV; Somlo, G; Straub, R; Swisher, EM; Yost, SE; Yuan, Y | 1 |
| Kang, S; Lin, Y; Lv, X; Song, C; Yu, Y; Zhang, J | 1 |
| Huo, X; Li, J; Ren, D; Shen, G; Wang, M; Zhao, F; Zhao, J; Zhao, Y | 1 |
| Cheng, Y; Cui, J; Lin, C; Peng, Z; Qian, K; Wu, R; Yin, W | 1 |
| Cheng, MY; Gao, HF; Ji, F; Li, JQ; Lin, YY; Wang, K; Yang, CQ; Yang, M; Yang, X; Zhang, LL; Zheng, XX; Zhu, T | 1 |
| Hong, X; Ren, X; Wang, D; Xie, K; Ye, X; Zhu, S | 1 |
| Dent, RA; Fink, JL; Jaradi, B; Koo, KM; Stone, N; Tan, DS; Tan, PH; Tan, TJ; Tay, TK; Waring, P | 1 |
| Dong, Q; Du, F; Gao, L; Huo, X; Li, Z; Liu, Z; Ren, D; Shen, G; Wang, M; Xie, Q; Xin, Y; Zhao, F; Zhao, J; Zhao, Y | 1 |
| Bei, T; Chen, Y; Cui, L; Du, F; Si, Y; Wang, X; Xu, B; Yuan, P; Yue, J; Zhang, B; Zhao, X | 1 |
| Belleville, E; Brucker, SY; Erber, R; Fasching, PA; Fehm, TN; Häberle, L; Hack, CC; Hartkopf, AD; Hartmann, A; Hein, A; Janni, W; Kolberg, HC; Rübner, M; Theuser, AK; Uhrig, S; Untch, M | 1 |
| Casini, A; Han, K; Maaty, MAAE; Ott, I; Schmidt, C; Song, J; Sun, H; Wölfl, S; Xu, QJ; Yu, C; Zhang, JJ; Zhou, J | 1 |
| Blanckenberg, A; Chakraborty, S; Chellan, P; Kimani, S; Mapolie, S; Prince, S; van Niekerk, A | 1 |
| Annunziato, S; Bièche, I; Chateau-Joubert, S; Courtois, L; Coussy, F; Dahmani, A; de Bruijn, R; de Ruiter, J; Decaudin, D; Derrien, H; Eeckhoutte, A; El-Botty, R; Huguet, L; Ibadioune, S; Jonkers, J; Kristel, P; Larcher, T; Lutz, C; Marangoni, E; Masliah Planchon, J; Montaudon, E; Morisset, L; Moser, SC; Nemati, F; Popova, T; Reyal, F; Salomon, A; Sourd, L; Stern, MH; Ter Brugge, P; Vacher, S; van der Burg, E; Wesseling, J | 1 |
| Ahad, A; Cerón-Carrasco, JP; Contel, M; Hafeez, A; León, IE; López-Hernández, JE; Nayeem, N | 1 |
| Abramson, VG; Boughey, JC; Cogan, ES; Connolly, RM; Dearden, S; Falkson, C; Ford, JM; Goetz, MP; Gradishar, WJ; Gutin, A; Hennessy, BT; Hodgson, DR; Jankowitz, RC; Kaklamani, VG; Lai, Z; Lanchbury, JS; Lenz, L; Marcom, PK; Mayer, EL; Mills, GB; Neff, C; Richardson, AL; Slavin, TP; Solimeno, C; Stearns, V; Storniolo, AM; Telli, ML; Timms, KM; Tung, NM; Vinayak, S | 1 |
| Beith, J; Dear, RF; Egger, SJ; Goodwin, A; Mason, SR; Willson, ML | 1 |
| Cormier, L; Lui, S; Middleton, L; Ndinguri, M; Nienaber, E; Rollins, J; Spease, C; Unrine, J; Williams, A | 1 |
| Abraham, DT; Backianathan, S; Balakrishnan, R; Chacko, RT; Cherian, AJ; George, TK; Georgy, JT; Joel, A; John, AO; Manipadam, MT; Patole, S; Paul, MJ; Ramnath, N; Rebekah, G; Sebastian, P; Sharma, P; Sigamani, E; Singh, A; Thumaty, DB | 1 |
| Gao, H; Kong, L; Ouyang, D; Sun, Y; Tu, K; Yang, C; Yang, T; Zhang, L; Zhang, Z | 1 |
| Chen, CK; Chen, M; Fan, SC; Huang, CS; Huang, TY; Kuo, SH; Lin, PH; Lo, C; Tsai, LW; Yen, TC | 1 |
| Benider, A; Jouhadi, H; Nadifi, S; Tazzite, A | 1 |
| Cai, P; Chai, Z; Gao, F; Gao, L; Gao, X; Han, X; He, Z; Jiang, H; Li, J; Niu, W; Wang, Y; Yuan, Q; Zhang, C; Zhao, L | 1 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Cao, J; Chen, Y; Du, YQ; Gong, CC; Hu, XC; Jin, J; Tao, ZH; Wang, BY; Wang, LP; Wang, ZH; Zhang, J; Zhao, YN | 1 |
| Ji, LN; Mao, ZW; Muhammad, N; Nasreen, S; Nawaz, U; Tan, CP; Wang, FX; Wang, J | 1 |
| Cao, XZ; Feng, Y; Li, ZY; Ren, SS; Zhang, Z | 1 |
| Lynce, F; Nunes, R | 1 |
| Awada, A; de Azambuja, E; Eiger, D; Ferreira, SC; Franzoi, MA; Saúde-Conde, R | 1 |
| Han, XH; Liu, S; Shi, YY; Yang, R | 1 |
| Arteaga, CL; Block, M; Burnette, BL; DeMichele, AM; Dewani, SJ; Flaum, LE; Garcia, SF; Jani, CR; Makower, DF; Mayer, EL; Mayer, IA; Mescher, C; Miller, KD; Morley, KA; Park, BH; Rodler, ET; Sikov, WM; Smith, KL; Sparano, JA; Symmans, WF; Tawfik, B; Tevaarwerk, AJ; Wagner, LI; Wolff, AC; Zhao, F | 1 |
| Ali, A; Bai, X; Hao, H; Lv, Z; Rahman, FU; Wang, N; Zhang, Y; Zhao, X | 1 |
| Gelmon, K; Rugo, HS | 1 |
| Bosdet, I; Bose, P; Ch'ng, C; Chia, S; Corbett, R; Den Brok, W; Eirew, P; Gelmon, K; Jones, M; Jones, SJM; Karsan, A; Kasaian, K; Laskin, J; Leelakumari, S; Lim, H; Lohrisch, C; Ma, Y; Marra, MA; Moore, RA; Mungall, AJ; Mungall, KL; Pleasance, E; Reisle, C; Renouf, D; Schein, JE; Schrader, KA; Shen, Y; Shenkier, T; Sun, S; Thiessen, N; Villa, D; Wilson, S; Yip, S; Young, S; Zhao, EY; Zhao, Y | 1 |
| Curigliano, G | 1 |
| Bozcuk, H; Gunduz, S; Kaya, V; Paydas, S; Yazici, G; Yildirim, M | 1 |
| Messina, C; Rediti, M | 1 |
| Cheang, MCU; Grigoriadis, A; Lord, CJ; Mirza, H; O'Shaughnessy, JA; Quist, J; Telli, ML; Tutt, ANJ | 1 |
| Amante, JJ; Elaimy, AL; FitzGerald, TJ; Goel, HL; Mercurio, AM; Walmsley, CS; Wang, M; Zhu, LJ | 1 |
| Baez-Revueltas, B; Bouganim, N; Clemons, M; Dent, R; Enright, K; Kassam, F; Khalaf, D; Kiss, A; Myers, J; Peña-Curiel, O; Pritchard, K; Verma, S; Villarreal-Garza, C | 1 |
| Cai, R; Fan, Y; Hong, R; Li, Q; Ma, F; Shi, X; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Ashworth, A; Cheang, MC; Ford, JM; Frankum, J; Gazinska, P; Gillett, C; Grigoriadis, A; Isaksson, A; Jasin, M; Joshi, S; Lord, CJ; Mayrhofer, M; Mirza, H; Pinder, S; Shah, V; Sidhu, B; Telli, ML; Tutt, AN; Vanoli, F; Vinayak, S; Watkins, J; Weekes, D | 1 |
| Abkevich, V; Barry, WT; Ford, JM; Garber, JE; Greene-Colozzi, A; Gutin, A; Hartman, AR; Hennessy, B; Iliev, D; Isakoff, SJ; Jensen, KC; Jones, JT; Lanchbury, JS; Mills, GB; Neff, C; Reid, J; Richardson, AL; Ryan, PD; Sangale, Z; Silver, DP; Szallasi, Z; Telli, ML; Timms, KM; Tung, NM; Winer, EP | 1 |
| Afghahi, A; Carlson, RW; Chang, PJ; Ford, JM; Hartman, AR; Jensen, KC; Kurian, AW; Schackmann, E; Telli, ML; Timms, KM; Vinayak, S | 1 |
| Sharma, P | 1 |
14 review(s) available for platinum and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Platinum-based systematic therapy in triple-negative breast cancer.
Topics: Anthracyclines; Biomarkers, Tumor; BRCA2 Protein; Humans; Platinum; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis.
Topics: Albumin-Bound Paclitaxel; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; B7-H1 Antigen; Bayes Theorem; Bevacizumab; Humans; Ligands; Neoadjuvant Therapy; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Taxoids; Triple Negative Breast Neoplasms; Zoledronic Acid | 2022 |
Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Humans; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Network Meta-Analysis; Platinum; Triple Negative Breast Neoplasms | 2023 |
Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estrogens; Humans; Platinum; Randomized Controlled Trials as Topic; Receptors, Progesterone; Triple Negative Breast Neoplasms | 2022 |
Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Network Meta-Analysis; Platinum; Taxoids; Triple Negative Breast Neoplasms | 2022 |
Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Nausea; Neutropenia; Platinum; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Topics: Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Female; Humans; Myalgia; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Platinum; Prognosis; Triple Negative Breast Neoplasms | 2023 |
Platinum-based chemotherapy for early triple-negative breast cancer.
Topics: Adjuvants, Immunologic; Anthracyclines; Carboplatin; Febrile Neutropenia; Humans; Platinum; Quality of Life; Triple Negative Breast Neoplasms | 2023 |
BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Circulating Tumor DNA; Female; Humans; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2020 |
Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Neoadjuvant Therapy; Platinum; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Role of Platinums in Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Neoadjuvant Therapy; Platinum; Triple Negative Breast Neoplasms | 2021 |
The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Platinum; Progression-Free Survival; Triple Negative Breast Neoplasms | 2021 |
Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis
Topics: Female; Humans; Platinum; Prognosis; Triple Negative Breast Neoplasms | 2018 |
Platinum-based chemotherapy in triple-negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Disease-Free Survival; Electronic Health Records; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Platinum; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
8 trial(s) available for platinum and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Endostatins; Female; Humans; Middle Aged; Platinum; Prospective Studies; Triple Negative Breast Neoplasms; Young Adult | 2021 |
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Female; Humans; Lymphopenia; Nausea; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Seizures; Triple Negative Breast Neoplasms | 2022 |
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Platinum; Prospective Studies; Quality of Life; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Platinum; Triple Negative Breast Neoplasms | 2021 |
[Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms, Second Primary; Platinum; Triple Negative Breast Neoplasms | 2014 |
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Topics: Allelic Imbalance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Loss of Heterozygosity; Mutation; Neoplasm Staging; Odds Ratio; Platinum; Prognosis; Telomere; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Tumor
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Carboplatin; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Triple Negative Breast Neoplasms | 2017 |
33 other study(ies) available for platinum and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Platinum; Triple Negative Breast Neoplasms | 2021 |
Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Pharmaceutical Preparations; Platinum; Triple Negative Breast Neoplasms | 2021 |
qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; DNA; Female; Homologous Recombination; Humans; Neoadjuvant Therapy; Platinum; Retrospective Studies; Triple Negative Breast Neoplasms | 2022 |
Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell-Free Nucleic Acids; Humans; Platinum; Triple Negative Breast Neoplasms | 2021 |
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoadjuvant Therapy; Platinum; Triple Negative Breast Neoplasms | 2022 |
[The prospects of DNA damage repair variants guiding platinum compounds in the treatment of triple negative breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; DNA Damage; DNA Repair; Humans; Pharmaceutical Preparations; Platinum; Platinum Compounds; Triple Negative Breast Neoplasms | 2022 |
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoadjuvant Therapy; Platinum; Triple Negative Breast Neoplasms | 2022 |
Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment.
Topics: Anthracyclines; BRCA1 Protein; BRCA2 Protein; Female; Genetic Testing; Humans; Platinum; Triple Negative Breast Neoplasms | 2022 |
Genomic and epigenomic
Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma; Epigenomics; Female; Genomics; Humans; Mutation; Ovarian Neoplasms; Platinum; Triple Negative Breast Neoplasms | 2022 |
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for
Topics: BRCA1 Protein; Genes, BRCA1; Humans; Methylation; Platinum; Triple Negative Breast Neoplasms | 2022 |
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; East Asian People; Homologous Recombination; Humans; Platinum; Retrospective Studies; Triple Negative Breast Neoplasms | 2023 |
Elucidating the Multimodal Anticancer Mechanism of an Organometallic Terpyridine Platinum(II) N-Heterocyclic Carbene Complex against Triple-Negative Breast Cancer In Vitro and In Vivo.
Topics: Apoptosis; Caffeine; Carbohydrates; Cell Line, Tumor; Cell Proliferation; Humans; Lipids; Nucleotides; Platinum; Triple Negative Breast Neoplasms | 2023 |
DNA-binding affinity and molecular docking studies of the PEGylated binuclear palladacycle, BTC2, an efficient metallodrug against triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; DNA; Humans; Ligands; Mammals; Molecular Docking Simulation; Platinum; Polyethylene Glycols; Triple Negative Breast Neoplasms | 2023 |
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Topics: BRCA1 Protein; BRCA2 Protein; Cisplatin; Homologous Recombination; Humans; Mutation; Platinum; Triple Negative Breast Neoplasms; Whole Genome Sequencing | 2023 |
Platinum(IV)-Gold(I) Agents with Promising Anticancer Activity: Selected Studies in 2D and 3D Triple-Negative Breast Cancer Models.
Topics: Antineoplastic Agents; Cell Line, Tumor; Gold; Humans; Oxaliplatin; Platinum; Triple Negative Breast Neoplasms | 2023 |
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Topics: BRCA1 Protein; BRCA2 Protein; Female; Genomic Instability; Homologous Recombination; Humans; Ovarian Neoplasms; Platinum; Triple Negative Breast Neoplasms | 2023 |
Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Female; Gonadotropin-Releasing Hormone; Humans; Platinum; Receptors, LHRH; Triple Negative Breast Neoplasms | 2023 |
Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Platinum; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
The novel platinum(IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Nanoparticles; Platinum; Prodrugs; Triple Negative Breast Neoplasms | 2020 |
Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Topics: BRCA1 Protein; BRCA2 Protein; DNA Damage; Female; High-Throughput Nucleotide Sequencing; Homologous Recombination; Humans; Middle Aged; Mutation; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2020 |
Is GSH Chelated Pt Molecule Inactive in Anti-Cancer Treatment? A Case Study of Pt
Topics: Animals; Antineoplastic Agents; Glutathione; Humans; Mice; Platinum; Platinum Compounds; Survival Analysis; Triple Negative Breast Neoplasms | 2020 |
Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Humans; Maintenance Chemotherapy; Platinum; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer.
Topics: Apoptosis; Cell Line, Tumor; Coordination Complexes; DNA Damage; Drug Liberation; Enzyme Inhibitors; Fluorouracil; Humans; Intracellular Space; Mitochondria; Platinum; Prodrugs; Reactive Oxygen Species; Thymidylate Synthase; Transcription, Genetic; Triple Negative Breast Neoplasms | 2020 |
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Humans; Middle Aged; Platinum; Prognosis; Receptor, ErbB-2; Retrospective Studies; Superior Vena Cava Syndrome; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
Topics: Antineoplastic Agents; Apoptosis; Autophagy-Related Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cellular Senescence; Coordination Complexes; Cyclin D1; Humans; L-Lactate Dehydrogenase; Molecular Conformation; Platinum; Proto-Oncogene Proteins c-bcl-2; Pyruvate Kinase; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Ubiquitin-Conjugating Enzymes | 2021 |
Use of Neoadjuvant Platinum-The Ongoing Conundrum.
Topics: Disease-Free Survival; Germ-Line Mutation; Humans; Neoadjuvant Therapy; Platinum; Triple Negative Breast Neoplasms | 2017 |
Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
Topics: BRCA1 Protein; BRCA2 Protein; Disease-Free Survival; Female; Homologous Recombination; Humans; Middle Aged; Mutation; Neoplasm Staging; Platinum; Treatment Outcome; Triple Negative Breast Neoplasms; Whole Genome Sequencing | 2017 |
Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
Topics: Benzimidazoles; Carboplatin; Humans; Neoadjuvant Therapy; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Salts; Standard of Care; Triple Negative Breast Neoplasms | 2018 |
Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Meta-Analysis as Topic; Neoadjuvant Therapy; Platinum; Precision Medicine; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.
Topics: Allelic Imbalance; Apoptosis Regulatory Proteins; Bayes Theorem; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase II as Topic; Decision Trees; DNA Repair Enzymes; Exodeoxyribonucleases; Female; Forkhead Box Protein M1; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Molecular Targeted Therapy; Platinum; Transcription Factors; Triple Negative Breast Neoplasms | 2019 |
The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.
Topics: Adaptor Proteins, Signal Transducing; BRCA1 Protein; Cell Line, Tumor; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Neuropilin-2; Neuropilins; Platinum; Rad51 Recombinase; Signal Transduction; Transcription Factors; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; YAP-Signaling Proteins | 2019 |
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.
Topics: Allelic Imbalance; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cell Survival; Chromosomal Instability; Cluster Analysis; DNA Copy Number Variations; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Gene Silencing; Genomics; Homologous Recombination; Humans; Platinum; Polymorphism, Single Nucleotide; RNA, Small Interfering; Triple Negative Breast Neoplasms | 2015 |
PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something "new" and something "old".
Topics: Breast Neoplasms; Cell Line, Tumor; Humans; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2017 |